[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335473-105":59,"doc-detail-335473-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-role-of-heparan-sulfate-in-enhancing-the-chemotherapeutic-response-in-triple-negative-breast-cancer","The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer","","Triple-negative breast cancer (TNBC) has the poorest outcomes among breast cancer subtypes due to therapies that fail to sustain responses. The study investigates how heparan sulfate and heparanase regulate extracellular ATP (eATP), which can stimulate purinergic signaling and influence chemotherapy sensitivity. Researchers treated TNBC and non-tumorigenic cells with paclitaxel alongside the heparanase inhibitor OGT 2115 and/or supplemental heparan sulfate, assessing viability, eATP release, and heparanase expression. They evaluated cancer-initiating cell populations via tumorsphere assays.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-of-heparan-sulfate-in-enhancing-the-chemotherapeutic-response-in-triple-negative-breast-cancer/335473/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-of-heparan-sulfate-in-enhancing-the-chemotherapeutic-response-in-triple-negative-breast-cancer/335473.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is improving chemotherapy response critical for triple-negative breast cancer (TNBC)?","Question",{"text":112,"@type":113},"TNBC shows the worst outcomes because existing therapies do not produce long-lasting responses, creating a need for more effective treatments that sustain efficacy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do heparan sulfate and heparanase relate to extracellular ATP (eATP) and treatment response?",{"text":117,"@type":113},"Heparan sulfate inhibits extracellular ATPases to help accumulate eATP, while heparanase degrades heparan sulfate. This balance is proposed to influence chemotherapy-induced changes in TNBC cell viability.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental treatments were used to test the proposed mechanism?",{"text":121,"@type":113},"TNBC cell lines MDA-MB-231, Hs 578t, and MDA-MB-468 and non-tumorigenic MCF-10A cells were treated with paclitaxel with or without the heparanase inhibitor OGT 2115 and/or supplemental heparan sulfate, followed by measurements of cell viability and eATP release.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335473,1790610116,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Manouchehri etal. Breast Cancer Research (2024) 26:153 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-024-01906-6](https://doi.org/10.1186/s13058-024-01906-6)  \nRESEARCH Open Access  \nThe role of heparan sulfate in enhancing the  chemotherapeutic response in triple-negative breast cancer  \nJasmine M. Manouchehri 1, Jharna Datta 1, Lynn M. Marcho 1, Jesse J. Reardon2, Daniel Stover 1, Robert Wesolowski 1, Uma Borate3, Ting-Yuan David Cheng4, Patrick M. Schnell5, Bhuvaneswari Ramaswamy 1, Gina M. Sizemore2, Mark P. Rubinstein 1 and Mathew A. Cherian 1,6*  \nAbstract  \nBackground Breast cancer, one of the most common forms of cancer, is associated with the highest cancerrelated mortality among women worldwide. In comparison to other types of breast cancer, patients diagnosed with the triple-negative breast cancer (TNBC) subtype have the worst outcome because current therapies do not produce long-lasting responses. Hence, innovative therapies that produce persisting responses are a critical need. We previously discovered that hyperactivating purinergic receptors (P2RXs) by increasing extracellular adenosine triphosphate (eATP) concentrations enhancesTNBC cell lines’ response to chemotherapy. Heparan sulfate inhibits multiple extracellular ATPases, so it is a molecule of interest in this regard. In turn, heparanase degrades polysulfated polysaccharide heparan sulfate. Importantly, previous work suggests that breast cancer and other cancers express heparanase at high levels. Hence, as heparan sulfate can inhibit extracellular ATPases to facilitate eATP accumulation, it may intensify responses to chemotherapy. We postulated that heparanase inhibitors would exacerbate chemotherapy-induced decreases inTNBC cell viability by increasing heparan sulfate in the cellular microenvironment and hence, augmenting eATP.  \nMethods We treated TNBC cell lines MDA-MB 231, Hs 578t, and MDA-MB 468 and non-tumorigenic immortal mammary epithelial MCF-10A cells with paclitaxel (cytotoxic chemotherapeutic) with or without the heparanase inhibitor OGT 2115 and/or supplemental heparan sulfate. We evaluated cell viability and the release of eATP. Also, we compared the expression of heparanase protein in cell lines and tissues by immunoblot and immunohistochemistry, respectively. In addition, we examined breast-cancer-initiating cell populations using tumorsphere formation efficiency assays on treated cells.  \nAn abstract of this work was previously presented at the American Association for Cancer Research (AACR) Annual Meeting (2023) .  \n*Correspondence:  \nMathew A. Cherian [mathew.cherian@osumc.edu](mathew.cherian@osumc.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nManouchehri et al. Breast Cancer Research (2024) 26:153 Page 2 of 14  \nResults We found that combining heparanase inhibitor OGT 2115 with chemotherapy decreased TNBC cell viability and tumors","cbCaiptGNHJRipxE","https://ap.wps.com/l/cbCaiptGNHJRipxE","pdf",2068147,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n## Keywords","[{\"question\":\"Why is improving chemotherapy response critical for triple-negative breast cancer (TNBC)?\",\"answer\":\"TNBC shows the worst outcomes because existing therapies do not produce long-lasting responses, creating a need for more effective treatments that sustain efficacy.\"},{\"question\":\"How do heparan sulfate and heparanase relate to extracellular ATP (eATP) and treatment response?\",\"answer\":\"Heparan sulfate inhibits extracellular ATPases to help accumulate eATP, while heparanase degrades heparan sulfate. This balance is proposed to influence chemotherapy-induced changes in TNBC cell viability.\"},{\"question\":\"What experimental treatments were used to test the proposed mechanism?\",\"answer\":\"TNBC cell lines MDA-MB-231, Hs 578t, and MDA-MB-468 and non-tumorigenic MCF-10A cells were treated with paclitaxel with or without the heparanase inhibitor OGT 2115 and/or supplemental heparan sulfate, followed by measurements of cell viability and eATP release.\"}]","The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer | PDF",1790011089,35]